Literature DB >> 23939917

Second primary malignancies following thyroid cancer: a population-based study in Taiwan.

Chang-Hsien Lu1, Kuan-Der Lee, Ping-Tsung Chen, Chih-Cheng Chen, Feng-Che Kuan, Cih-En Huang, Miao-Fen Chen, Min-Chi Chen.   

Abstract

OBJECTIVE: Most studies on second primary malignancies (SPMs) after primary thyroid cancer were conducted in USA or Europe. The discrepancy between SPMs in these studies could be attributed to geographical and ethnic heterogeneity. Thus, there is a clear need for another large-scale epidemiological study, particularly in Asian countries, to define the incidence and risk of SPMs in thyroid cancer survivors.
DESIGN: A population-based study was conducted using the nation-wide database from Taiwan Cancer Registry between 1979 and 2006.
METHODS: We quantified standardized incidence ratios (SIRs) and cumulative incidence of SPMs among 19,068 individuals (4205 males and 14,863 females) with primary thyroid cancer.
RESULTS: A total of 644 cases (3.38%) developed at least a SPM during 134,678 person-years of follow-up. The risk for subsequent SPMs was significantly greater than that of the general population (SIR=1.33, 95% CI 1.23-1.44). There was a greater risk of developing major salivary glands, nasopharyngeal, lung, thymus, breast (females), bladder, and brain cancers, and leukemia and lymphoma. We observed that the risk was highest within the first 5 years of diagnosis of thyroid cancer (SIR=5.29, 1.68, and 0.68 for ≤ 5, 5-10, and >10 respectively) and in the younger patients (SIR=1.81 vs 1.61 for <50 and ≥ 50 respectively). The median overall survival for primary thyroid cancer patients was 23.28 years, but it was only 4.73 years for those who developed SPMs.
CONCLUSION: Thyroid cancer is associated with a 33% risk increment of SPMs, which had a negative impact on survival. There are sites of SPMs in the Asian population that are distinctive from those in the Western population, suggesting that other genetic predisposition or environmental factors may play a role.

Entities:  

Mesh:

Year:  2013        PMID: 23939917     DOI: 10.1530/EJE-13-0309

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  20 in total

1.  Radioactive Iodine-Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival.

Authors:  Laura Boucai; John Falcone; Jenny Ukena; Catherine C Coombs; Ahmet Zehir; Ryan Ptashkin; Michael F Berger; Ross L Levine; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

Review 2.  The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis.

Authors:  Sarah M Nielsen; Michael G White; Susan Hong; Briseis Aschebrook-Kilfoy; Edwin L Kaplan; Peter Angelos; Swati A Kulkarni; Olufunmilayo I Olopade; Raymon H Grogan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02       Impact factor: 4.254

3.  Risk of second malignancies among survivors of pediatric thyroid cancer.

Authors:  Marwan H Adly; Mohamed Sobhy; Mohamed A Rezk; Medhat Ishak; Mahmoud A Afifi; Ayman El Shafie; Mahmoud Ahmed Ali; Wael Zekri; Ahmad Samir Alfaar; Wafaa M Rashed
Journal:  Int J Clin Oncol       Date:  2018-02-28       Impact factor: 3.402

4.  Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.

Authors:  Tommi T Hakala; Juhani A Sand; Arja Jukkola; Heini S Huhtala; Saara Metso; Pirkko-Liisa Kellokumpu-Lehtinen
Journal:  Int J Clin Oncol       Date:  2015-09-26       Impact factor: 3.402

5.  Survival impact of locoregional metachronous malignancy in survival of lung cancer patients who received curative treatment.

Authors:  Chi-Tsung Wen; Jui-Ying Fu; Ching-Feng Wu; Ming-Ju Hsieh; Yun-Hen Liu; Yi-Cheng Wu; Ying-Huang Tsai; Ching-Yang Wu
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

6.  Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.

Authors:  Nicholas Donin; Christopher Filson; Alexandra Drakaki; Hung-Jui Tan; Alex Castillo; Lorna Kwan; Mark Litwin; Karim Chamie
Journal:  Cancer       Date:  2016-07-05       Impact factor: 6.860

7.  THYROID MALIGNANCY RISK OF INCIDENTAL THYROID NODULES IN PATIENTS WITH NON-THYROID CANCER.

Authors:  M M Yalcin; A E Altinova; C Ozkan; F Toruner; M Akturk; O Akdemir; T Emiroglu; D Gokce; A Poyraz; F Taneri; I Yetkin
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Apr-Jun       Impact factor: 0.877

8.  Thyroid disease is associated with an increased risk of breast cancer: a systematic review and meta-analysis.

Authors:  Shi Chen; Fei Wu; Rui Hai; Qian You; Linjun Xie; Liang Shu; Xiangyu Zhou
Journal:  Gland Surg       Date:  2021-01

9.  Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.

Authors:  Remco J Molenaar; Surbhi Sidana; Tomas Radivoyevitch; Anjali S Advani; Aaron T Gerds; Hetty E Carraway; Dana Angelini; Matt Kalaycio; Aziz Nazha; David J Adelstein; Christian Nasr; Jaroslaw P Maciejewski; Navneet S Majhail; Mikkael A Sekeres; Sudipto Mukherjee
Journal:  J Clin Oncol       Date:  2017-12-18       Impact factor: 50.717

10.  Thymic Carcinomas and Second Malignancies: A Single-Center Review.

Authors:  Sunil S Badve; Rachel Dougherty; Michael Balatico; Kenneth A Kesler; Patrick Loehrer; Yesim Gökmen-Polar
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.